Current Treatment Strategies for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Clinical Diabetes and Endocrinology - United Kingdom
doi 10.1186/s40842-018-0066-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Circulating Markers in Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)

2012English

Comprehensive Genomic Profiling of 724 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs).

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2018English

Catecholamine Production in Patients With Gastroenteropancreatic Neuroendocrine Tumors

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
1999English

Resistance to Targeted Treatment of Gastroenteropancreatic Neuroendocrine Tumors

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2019English

Identification of Primary Tumors in Patients Presenting With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Surgery
Surgery
2017English

Risk Factors Associated With Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in a Cohort of 2.3 Million Israeli Adolescents

International Journal of Cancer
Cancer ResearchOncology
2018English

Lanreotide vs Octreotide LAR for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors: An Observational Time and Motion Analysis

Journal of Oncology Pharmacy Practice
MedicineOncologyPharmacology
2019English

Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature

International Journal of Surgical Oncology
SurgeryOncology
2017English

MicroRNA Analysis of Gastroenteropancreatic Neuroendocrine Tumors and Metastases

Oncotarget
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy